TAP2 and fibrosarcoma: In order to avoid confounding immunity to the RMA/S cells themselves (Van Hall et al., 2006), we used CRISPR/Cas9 to generate a B6-syngeic Tap2-/- MCA205 fibrosarcoma cell line.